September 1, 2011, Toronto, Ontario: Functional Neuromodulation Inc, a company advancing deep brain stimulation (DBS) therapies for Alzheimer’s disease, has named industry leader Todd Langevin president and COO. Langevin will spearhead the Company’s internal operations and clinical research program.
“Todd’s unparalleled expertise in expanding clinical applications and accelerating market adoption of DBS therapy will be a key driver for our success,” said Dan O’Connell, Functional Neuromodulation co-founder and CEO. “Todd’s 20-year tenure with DBS pioneer Medtronic puts him in an excellent position to lead Functional Neuromodulation’s development of DBS to improve memory and cognition in people with early Alzheimer’s.”
Langevin is a seasoned leader in neuromodulation, having served as vice president and general manager of Medtronic’s Movement Disorders business, which includes DBS products for treating Parkinson's disease, essential tremor and dystonia; and the SynchroMed pump for delivery of intrathecal baclofen for spasticity.
For five years, Langevin managed sales, marketing and customer education for Medtronic’s neurological business in Europe. Prior to his European assignment, he had global market development responsibilities for an implantable spinal cord stimulator for chronic pain, and led a team which developed and launched novel therapies for the treatment of movement disorders. Prior to joining Functional Neuromodulation, Langevin was senior vice president of clinical operations and commercial development for CVRx, Inc., a company engaged in the development of an implantable device to regulate hypertension.
“I am excited about the potential for DBS to be a game-changing advance in the treatment of Alzheimer’s disease and other cognitive disorders,” said Langevin. “Functional Neuromodulation is taking a completely different approach from current medications by utilizing DBS of the fornix to stimulate the brain’s memory circuit and restore memory function.”
About Deep Brain Stimulation
Deep brain stimulation (DBS) uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain.
Medtronic, in collaboration with leading physicians around the world, pioneered deep brain stimulation therapy, which was first approved in Europe in 1995 and the United States in 1997. More than 80,000 people worldwide have received Medtronic DBS Therapy.
About Functional Neuromodulation, Ltd.
Based in Toronto, Ontario, Functional Neuromodulation Inc. is dedicated to advancing deep brain stimulation (DBS) therapies to improve the lives of people with Alzheimer’s and other memory and cognitive disorders.
CAUTION — Investigational device. Limited by Federal law to investigational use.
Functional Neuromodulation, Ltd. | 2355 Hwy 36 W | 4th Floor | Minneapolis, MN 55113 | email@example.com
© 2014 Functional Neuromodulation Ltd. All rights reserved.